GlassScriptPhysician profile
Michael David Hoffstetter
NPI 1780840819
$463.83
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $36.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $86.62 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $72.33 | 2019 | |
| Avanir Pharmaceuticals, INC. | $67.65 | 2019 | |
| Eisai INC. | $61.44 | 2019 | |
| Lilly USA, LLC | $55.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $19.97 | 2019 | |
| Acorda Therapeutics, INC | $19.93 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.15 | 2019 | |
| Tanabe Pharma America, INC. | $14.89 | 2019 | |
| Ge Healthcare | $13.64 | 2019 | |
| Ucb, INC. | $12.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hoffstetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.